Astrazeneca (AZN)

 

AZN Share PerformanceMore

52 week high5,520 22/06/17
52 week low4,137 27/01/17
52 week change 431 (9.41%)
4 week volume36,623,396 22/12/17

Latest NewsMore

Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and set its price target ...

Broker Forecast - Exane BNP Paribas issues a broker note on AstraZeneca PLC

Exane BNP Paribas today reaffirms its outperform investment rating on AstraZeneca PLC (LON:AZN) and set its price ta...

FDA approves Lynparza for metastatic breast cancer

RNS Number: 7898B AstraZeneca PLC 12 January 2018 12 January 2018 16:10 GMT LYNPARZA APPROVED BY US FDA IN GERMLINE BRCA -MUTATED METASTATIC BREAST CANCER Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Lynparza reduced the risk of disease progression or death by 42% compared to sta...

David Buik's stocks to follow in 2018

Leading market commentator David Buik tells Interactive Investor who he thinks the winners will be this year and where...

Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC

Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and set its price target at 5700p...

AstraZeneca's Fasenra approved in the EU

RNS Number: 5204B AstraZeneca PLC 10 January 2018 10 January 2018 15:10 GMT FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA Approval based on Phase III WINDWARD programme that demonstrated significant reductions in asthma exacerbations, improvements in lung function and reductions in oral corticosteroid use from...

Total Voting Rights

RNS Number: 7321A AstraZeneca PLC 02 January 2018 2 January 2018 15:00 GMT Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 December 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,266,221,605...

Director/PDMR Shareholding

RNS Number: 4358A AstraZeneca PLC 28 December 2017 28 December 2017 14:00 GMT TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES - AMENDMENT Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements...

Latest discussion posts More

  • AstraZeneca lung cancer drug granted priority review in US

    The US Food and Drug Administration has accepted AstraZeneca's regulatory submission for Tagrisso for the treatment of patients with metastatic non-small cell lung cancer. ...
    18-Dec-2017
    Proverbs 26 vs 5
  • AZ submits Tagrisso application in Japan

    AstraZeneca has submitted a supplemental new drug application for its lung cancer drug Tagrisso to Japan's Pharmaceuticals and Medical Devices Agency. AstraZenecahas submitted ...
    27-Nov-2017
    Proverbs 26 vs 5
  • NEW ARTICLE: How I am preparing for a stockmarket correction

    "When Equilibrium's Mike Deverell built our Long-Term Growth portfolio in the spring, he was cautious about the stockmarket. Holly Black reports on what's changed since.With ...
    8-Nov-2017
    II Editor

Users' HoldingsMore

Users who hold Astrazeneca also hold..
HSBC HLDGS.UK100%
IGAS ENERGY66%
MAN GROUP66%
TESCO66%
ISH COREFTSE10066%

Codes & Symbols

ISINGB0009895292
SymbolsAZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account